A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2012
At a glance
- Drugs Cyclophosphamide; Docetaxel; Epirubicin
- Indications Breast cancer
- Focus Adverse reactions
- 05 Jun 2012 New source identifed and integrated: ClinicalTrials.gov record NCT00189670.
- 05 Nov 2010 New trial record.